TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02771730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral sucrose capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
Study: NCT05232513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
Study: NCT02977884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Complete Health Improvement Program
Description: CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
Study: NCT01597505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: 250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
Study: NCT00910520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Study: NCT03987256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial rehabilitation protocol
Description: During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial rehabilitation protocol
Description: During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needling with PRP
Description: In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needling with saline solution
Description: In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure.
Study: NCT03467438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-l-carnosine
Description: Patients will be asked to take the investigational product as already mentioned (blindly).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to take placebo as already mentioned (blindly).
Study: NCT03064854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Subcutaneous injection
Study: NCT00452673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
Study: NCT01582178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Water Immersion Colonoscopy
Description: Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cool Water Immersion Colonoscopy
Description: Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
Study: NCT03414996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
Study: NCT03911661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fearon warfarin dosing algorithm
Description: Blood test drawn by patient using a point of care INR monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fearon warfarin dosing algorithm
Description: Blood test drawn by patient using a point of care INR monitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Historical management of warfarin by patient's usual care providers
Study: NCT02937142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior group therapy
Description: 1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Education on ADHD, and ADHD medication if indicated

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Education on ADHD, and ADHD medication if indicated
Study: NCT00130793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation
Description: 1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: zoster vaccine live (Oka/Merck) frozen formulation
Description: 1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
Study: NCT04110366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: Vaccination with live attenuated influenza vaccine (LAIV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle control
Description: Vehicle control nasal challenge
Study: NCT02406989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MS-553
Study: NCT00818064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)
Study: NCT05016011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: Human umbilical cord-derived mesenchymal stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow cellution
Description: Patients will undergo marrow cellution surgical procedure.
Study: NCT01002664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2
Description: 30 mg/day (two 15 mg capsules) Qd for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 soft-gel placebo capsules Qd for 12 weeks
Study: NCT01610232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon stimulation by light-emitting diodes (LEDs)
Description: Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
Study: NCT03856996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stable CH505TF gp120
Description: Administered by IM injection in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transient CH505TF gp120
Description: Administered by IM injection in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
Description: Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
Description: Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
Study: NCT00633737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction intervention
Description: In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
Study: NCT01003639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Formal weight loss counselling program
Description: Teleconference, web-based from central location, using site visits and subject self-assessment tools

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Formal weight loss counselling program
Description: Teleconference, web-based from central location, using site visits and subject self-assessment tools
Study: NCT02914379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3337641
Description: Administered orally
Study: NCT03126032

Intervention type: OTHER
Intervention: GlycoCheck™-System
Description: Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay.

Intervention type: OTHER
Intervention: GlycoCheck™-System
Description: Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay.

Intervention type: OTHER
Intervention: GlycoCheck™-System
Description: Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay.